Home » Newsletters » BioWorld Science

BioWorld Science

March 30, 2012

View Archived Issues

Virus-mediated neuroprotection demonstrated in model of Parkinson's disease

New protein kinase modulators designed by Ambit Biosciences

Lexicon Pharmaceuticals provides first description of early development of LX-4211

Researchers at Vertex Pharmaceuticals identify new selective PLK1 inhibitor

Gruenenthal team prepares novel voltage-gated potassium channel modulators

Merck & Co. synthesizes novel ERK inhibitors

Scientists at Merck KGaA patent new protein kinase inhibitors

Anacetrapib improves dyslipidemia in Japanese trial

Antisense therapy shows promise in phase I study

New details disclosed on phase I cenderitide trial

Abide Therapeutics and Scynexis announce collaboration

Phase I trials of e-Therapeutics anticancer drug clear to proceed

FDA clarifies dose and warning recommendations for antidepressant

SymBio's notification for phase I rigosertib study accepted in Japan

Kiklin capsules approved in Japan

U.S. university researchers prepare novel c-Met inhibitors

GSK and DSP set to copromote antidepressant in Japan

Apokyn approved for marketing in Japan

New mTOR inhibitors presented by Merck & Co.

Zeria files for approval of oral phosphate hypophosphatemia drug in Japan

Chugai obtains approval in Japan for cystic fibrosis treatment

Toray and Taiho discontinue codevelopment of beta3-adrenoceptor agonist

Pfizer and Astellas amend Lipitor licensing agreement

New product approved for T-cell leukemia-lymphoma

GenSpera advances phase I study of lead chemotherapeutic agent

Optimer and Astellas enter commercialization agreement for fidaxomicin tablets

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.